EditorialKommentar
Intensive Glucose Control in Critically Ill Patients — How Low Do We Go?
NEJM Evidence · 2024
DOI: 10.1056/evide2400196 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, 2024. Verfasst von Shohinee Sarma. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Critical Illness, Blood Glucose. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Critical IllnessBlood GlucoseHumansHyperglycemiaCritical CareGlycemic ControlHypoglycemic AgentsIntensive Care UnitsInsulin
Substanzen
Blood GlucoseHypoglycemic AgentsInsulin
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.
Zitieren
APA
Sarma, S. (2024). Intensive Glucose Control in Critically Ill Patients — How Low Do We Go?. NEJM Evidence. https://doi.org/10.1056/evide2400196
Vancouver
Sarma S. Intensive Glucose Control in Critically Ill Patients — How Low Do We Go?. NEJM Evidence. 2024. doi:10.1056/evide2400196
BibTeX
@article{Sarma2024,
author = {Sarma, Shohinee},
title = {Intensive Glucose Control in Critically Ill Patients — How Low Do We Go?},
journal = {NEJM Evidence},
year = {2024},
doi = {10.1056/evide2400196}
}
EUVIMED